Sciwind Biosciences Announces Positive Interim Results from Ongoing Phase 2b Clinical Trial of XW003 (Ecnoglutide) in Patients with Obesity

–  Mean body weight loss of 11.1% in participants receiving once-weekly injections of 2.4 mg XW003 for 18 weeks

–  88.5% and 57.7% of participants receiving 2.4 mg XW003 for 18 weeks achieved weight loss of ≥5% and ≥10%, respectively 

– XW003 was safe and well tolerated, with an adverse event profile consistent with other GLP-1 analogs

Excerpt from the Press Release:

SAN FRANCISCO and HANGZHOU, China, Oct. 27, 2022 /PRNewswire/ — Sciwind Biosciences, a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, announced today positive results from an interim analysis of the on-going Phase 2b clinical trial of XW003 (ecnoglutide) in patients with obesity. XW003 is a novel, long-lasting glucagon-like peptide-1 (GLP-1) analog being developed for the treatment of type 2 diabetes and obesity.

XW003 is currently being studied in a multi-center, open-label, active-controlled Phase 2b clinical trial in participants with a body mass index (BMI) ≥30 kg/m². The trial is being conducted at nine sites in Australia and New Zealand, with 206 participants enrolled. Participants were randomized to receive target doses of XW003 at 1.2, 1.8, or 2.4 mg as once weekly injections or liraglutide (Saxenda®) at 3.0 mg as once daily injections for 26 weeks. Doses were increased by titration for up to 14 weeks before reaching the target dose. The interim analysis was conducted when approximately 140 participants had completed 18 weeks of treatment. At baseline, participants had a mean body weight of 99.6 kg and BMI of 34.9 kg/m².

After 18 weeks of treatment, participants receiving 2.4 mg XW003 weekly achieved a mean body weight reduction from baseline of 11.1% (10.9 kg), compared to 7.9% (8.1 kg) for participants receiving 3.0 mg liraglutide daily injections (P=0.009). After 18 weeks of treatment, the proportion of participants achieving ≥5% body weight loss from baseline was 88.5% for 2.4 mg XW003 and 70.4% for liraglutide, while those reaching ≥10% body weight loss from baseline was 57.7% for 2.4 mg XW003 and 33.3% for liraglutide.

Click the button below to read the entire Press Release:

Continue Reading The Press Release